ArriVent BioPharma Inc. C...

NASDAQ: AVBP · Real-Time Price · USD
19.45
0.83 (4.46%)
At close: Aug 15, 2025, 12:43 PM

ArriVent BioPharma Common Stock Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a
Operating Income
-94.31M -74.59M -36.91M -8.7M
Interest Income
13.82M 5.26M n/a n/a
Pretax Income
-80.49M -69.33M -36.91M -51.61M
Net Income
-80.49M -69.33M -36.91M -51.61M
Selling & General & Admin
15.3M 9.71M 6.47M 2.26M
Research & Development
79M 64.88M 30.43M 6.43M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
94.31M 74.59M 36.91M 8.7M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a -754K
Cost & Expenses
-94.31M 74.59M 36.91M 8.7M
Income Tax Expense
n/a n/a n/a -11.59M
Shares Outstanding (Basic)
31.47M 31.96M 33.49M 1.28M
Shares Outstanding (Diluted)
31.47M 31.96M 33.49M 1.28M
EPS (Basic)
-2.56 -2.17 -1.1 -40.44
EPS (Diluted)
-2.56 -2.17 -1.1 -40.44
EBITDA
-80.49M -74.59M -36.91M -51.61M
EBIT
-80.49M -74.59M -36.91M -11.59M
Depreciation & Amortization
n/a n/a 36.91M 11.59M